Finally, you are the one of very few people say it very honestly.
Most of the longs are either blind or refuse to admit it. There is something wrong behind it to cause company keeps saying "quiet period". I am long and I believe data is positive if OS is primary endpoint. So far, there is no prove that FDA agree OS is primary endpoint.
If FDA doesn't take any action to agree? then company can continue to wait endless and says it is in the quiet period. I even doubt any journal is working on it at all. Company would wait for acceptance from FDA, then ask Journal to write it, in the meantime, release TLD. Few months later, article from Journal also will be out. Similar to AMRN's case.
Right now, NWBO management doing opposite way to approach journal publication first. Think about this way, if FDA doesn't agree to change OS as primary endpoint, any journal article would be useless.
Some people in this board insist company would not do data lock without acceptance of new SAP from all 4 agencies. I think this answer is by assumption, just a guess. I believe this last year but I doubt it now because this quiet period is way too long.
Be prepare that company keeps saying "quiet period" for a long time in year 2022 & 2023 even though company receive manufacture certificate from MHRA later this year or early in year 2022.
AI
Market Data 
Markets 
